Many primary tumours have low levels of molecular oxygen (hypoxia). Hypoxic tumours are more likely to metastasize to distant sites and respond poorly to multiple therapies. Surprisingly, then, the pan-cancer molecular hallmarks of tumour hypoxia remain poorly understood, with limited understanding of its associations with specific mutational processes, non-coding driver genes and evolutionary features. To fill this gap, we quantified hypoxia in 1,188 tumours spanning 27 cancer types. We show that elevated hypoxia is associated with increased mutational load across cancers, irrespective of the underlying mutational class. The proportion of mutations attributed to several mutational signatures of unknown aetiology are directly associated with the level of hypoxia, suggesting underlying mutational processes for these signatures. At the gene level, driver mutations in TP53, MYC and PTEN are enriched in tumours with high hypoxia, and mutations in PTEN interact with hypoxia to direct the evolutionary trajectory of tumours. Overall, this work demonstrates that hypoxia plays a critical role in shaping the genomic landscape of cancer. Bhandari et al. 
Introduction
Approximately half of all solid tumours are characterized by low levels of molecular oxygen (hypoxia) [1] [2] [3] [4] . Sub-regions of hypoxia can result from disrupted oxygen supply: irregular and disorganized tumour vasculature can reduce oxygen availability 5 . Hypoxia can also be caused by changes in oxygen demand: altered tumour metabolism 6, 7 can increase intra-cellular demand for oxygen, potentially extending hypoxia signalling to liquid tumours. The adaptation of tumour cells to this imbalance in oxygen supply and demand is associated with poor clinical prognosis in several cancer types, attributed at least in part to hypoxia-associated genomic instability and clonal selection [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Previous work has provided insight into the molecular origins and consequences of tumour hypoxia and genomic instability. Dynamic cycling of hypoxia can select for cells with TP53 mutations and for those that are apoptosis-deficient 17, 18 . Indeed mutations in TP53 occur at a higher frequency in hypoxic primary tumours of at least 9 types 16 . The abundance of proteins involved in homologous recombination (e.g.
RAD51
) and hon-homologous end joining (e.g. Ku70) are reduced under hypoxia, and these changes can persist for two days after reoxygenation [19] [20] [21] . Genes central to efficient mismatch repair (e.g. MLH1 and MSH2) are also downregulated under hypoxia 22, 23 . Further, co-presence of tumour hypoxia and high genomic instability 14, 15 , specific cellular morphologies like intraductal and cribriform carcinoma 24 or specific mutations like loss of PTEN 16 , synergistically predict for rapid relapse after definitive local therapy in some tumour types, particularly prostate cancer. These data underscore the relationship between hypoxia and DNA repair defects, and suggest the tumour microenvironment applies a selective pressure leading to the development of specific genomic profiles.
We previously evaluated the exomic and copy-number alteration (CNA) consequences of tumour hypoxia across 19 cancer types 16 . However, the influence of tumour hypoxia on pan-cancer driver alterations, mutational signatures and subclonal architectures remains unclear. To fill this gap, we calculated tumour hypoxia scores for 1,188 tumours with whole-genome and RNA-sequencing sequencing, spanning 27
cancer types. This high-quality harmonized dataset represents a powerful hypothesisgenerating mechanism to suggest useful back-translational in vitro experiments and better define the hypoxia-associated mutator phenotype. We associated hypoxia with key driver alterations in coding and non-coding regions of the genome, and find hypoxia is associated with specific mutational signatures of unknown aetiology. We illustrate the joint impact of PTEN and the tumour microenvironment in influencing the evolutionary trajectory of tumours. Overall, these data highlight the genomic changes through which hypoxia drives aggressive cancers.
Results

The pan-cancer landscape of tumour hypoxia
We compiled a cohort of 1,188 tumours from 27 cancer types in the Pan-Cancer
Analysis of Whole Genomes (PCAWG) dataset with matched tumour/normal wholegenome sequencing and tumour RNA sequencing data. Whole-genome sequencing 25 and RNA-sequencing 26 analyses were systematically carried out by centralized teams with consistent bioinformatics pipelines. Normal samples had a mean whole-genome sequencing coverage of 30 reads per base-pair while coverage for tumour samples had a bimodal distribution with maxima at 38 and 60 reads per base-pair 25 . All samples underwent an extensive and systematic quality assurance process 25 .
We used linear mixed-effect models to associate hypoxia with features of interest across cancers while adjusting for age. Cancer type and sex were further incorporated as random effects in every model, allowing us to consider a different baseline value for the feature of interest for each cancer type and sex 27 . As a measure of effect size, we report
values which reflect the variance explained by the fixed and random factors in each model 28 .
We scored tumour hypoxia in all 1,188 tumours using a trio of mRNA-based hypoxia 
The genomic correlates of tumour hypoxia
To determine whether genomic instability arising from specific mutational classes is associated with hypoxia, we looked to identify hypoxia-associated pan-cancer mutational density and summary features 32 . We first considered as a positive control the percentage of the genome with a copy-number aberration (PGA), an engineered feature that is a surrogate for genomic instability and is associated with hypoxia across several tumour types 16 ( Supplementary Figure 2f) . Indeed, in this diverse pan-cancer cohort, hypoxic tumours have elevated genomic instability while controlling for cancer type, age and sex 27 We then considered the association of hypoxia scores with 14 other metrics of the mutation density of CNAs, structural variants (SVs) and single nucleotide variants (SNVs) using linear mixed-effect models (Figure 2a, Supplementary Figure 2f Considering the strong association of hypoxia with mutational density, we next looked to determine if these were only general effects or selectively affected specific genes or chromosome regions. We leveraged a catalog of 653 driver mutations 33 , with CNA, SV and SNV data available for 1,096 patients. In cases where a patient had multiple mutations in the same gene (e.g. a CNA and an SNV) we denoted these as compound events. We again used linear mixed-effect models to associate hypoxia with each driver feature across cancers (Figure 2b) . Adjusting for cancer type, age and sex, 10 driver events were associated with hypoxia across cancers (FDR < 0.10, 
Hypoxia associated mutational signatures
Previous work has used nonnegative matrix factorization to identify distinct mutational processes in cancer cells from endogenous and exogenous agents 34 . To identify hypoxia-associated mutational processes, we tested if hypoxia score was associated with the proportion of mutations attributed to each mutational signature using linear mixed-effect models. Of the 65 single base substitution (SBS) signatures tested, 9 showed differential activity in hypoxic tumours compared to non-hypoxic ones while controlling for cancer type, age and sex (FDR < 0.10, linear mixed-effect models; Figure 3a , Supplementary Table 6 ). Of these, six were more active and three less active in tumours with elevated hypoxia. Since previous work has shown that DNA repair is impaired under hypoxia, it was not surprising to observe that a higher proportion of mutations were attributed to SBS3 in tumours with elevated hypoxia score (FDR = 2.01 x 10 
The subclonal hallmarks of tumor hypoxia
State-of-the-art methods for subclonal reconstruction rely on whole-genome sequencing data 35 , making the PCAWG dataset an ideal place to understand the evolutionary pressures imposed by hypoxia. Our group and others have shown that some mutations consistently occur early during tumorigenesis while others occur later and that hypoxia is associated with CNAs occurring early in localized prostate cancer 16, 36, 37 . 
Discussion
Hypoxia is a feature of many solid and liquid tumours and is associated with aggressive disease. We calculated hypoxia scores for 1,188 tumours from 27 cancer types and showed the vast heterogeneity that exists in this microenvironmental feature within and across cancer types. This reinforces previous pushes for careful patient selection in prospective trials of hypoxia-targeting agents 16 . Further, this work prompts the consideration of basket trials for hypoxia targeting agents to help patients with elevated hypoxia across several cancer types.
For the first time, we characterized the pan-cancer whole-genome correlates of tumour hypoxia. We show the broad influence of the hypoxia associated mutator is particularly difficult and these data provide a high confidence measure of the mutational signatures that may be directly or indirectly driven by tumour oxygen levels. It is difficult to disentangle the timing of these events: whether a specific driver mutation gives rise to a specific mutational signature or if these are separate processes. Better mapping of the evolutionary timing of hypoxia will be particularly important in addressing this question and the advent of hypoxia signatures may facilitate future studies in this area.
We observed a significant association between elevated hypoxia and the number of clonal mutations. This supports the idea that hypoxia is an early event in cancer, as we have suggested previously 16 , and other models that link hypoxia to genomic instability and downstream clonal selection 20, 41 . Previous work has also demonstrated that patients with allelic loss of PTEN and elevated hypoxia rapidly relapse after definitive treatment for localized prostate cancer 16 . Here, we showed that tumours with alterations in PTEN and elevated hypoxia are enriched for a polyclonal tumour architecture. This illustrates the joint influence of the tumour mutational landscape and microenvironment in guiding evolutionary trajectories across cancers. Further, these data suggest that increased subclonal diversification may be a novel route via which PTEN drives aggressive tumour phenotypes, in concert with tumour hypoxia, and this can be better defined with future back-translational in vitro experiments.
Overall, this work shows that a hypoxic tumour microenvironment is associated with specific mutational processes and distinct somatic mutational profiles, and may direct the subclonal architecture of cancers.
Methods
Pan-cancer hypoxia scoring
Hypoxia scores were calculated for all 1,188 tumours with mRNA abundance data using mRNA-abundance based signatures of tumour hypoxia developed previously by
Winter et al., 30 Buffa et al. 29 and Ragnum et al. 31 , as described previously 14, 16 (Supplementary Table 2 ). Briefly, patients with the top 50% of mRNA abundance values for each gene in a signature were given a score of +1. Patients with the bottom 50% of mRNA abundance values for that gene were given a score of -1. This was repeated for every gene in the signature to generate a hypoxia score for each patient, and this process was repeated for each of the three signatures used in the study. High scores suggest that the tumour was hypoxic and low scores are indicative of normoxia.
Hypoxia Score Comparison
To compare hypoxia scores generated by the different signatures, the median hypoxia score was calculated for each of the PCAWG cancer types based on each signature.
The median hypoxia scores from each signature were then scaled from +1 to -1 using the plotrix package (v3.7). Scaled median hypoxia values for the PCAWG cancer types were also compared to scaled median hypoxia values from previously 
Linear Mixed-Effect Models
We used linear mixed-effect models to associate hypoxia with features of interest (e.g., PGA, TP53 mutational status, etc.) across cancers using the lme4 package (v1.1-17). For each feature of interest we compared a full model (i.e., a model with the feature of interest) to a null model (i.e. a model without the feature of interest) using an ANOVA to determine if hypoxia was significantly associated with the feature of interest across cancers:
All models were adjusted for patient age. Cancer type and sex were used as random effects in every model. This allows us to consider a different baseline value for the feature of interest for each cancer type and sex 27 . For each model an
value is reported, reflecting the variance explained by the fixed and random factors 28 .
All model diagnostics were done using the DHARMa package (0.2.0) which uses a simulation-based approach to create standardized residuals 43 . For each model, scaled residuals were generated using the simulateResiduals function. The full model was used as the input for fittedModel parameter and 1,000 simulations were run. For correctly specified models, the scaled residuals were expected to be uniformly distributed and this was verified for each full model. We also compared the standardized residuals to the rank transformed predicted values to assess deviations from uniformity for each full model.
Mutational Density Analysis
Previously published data for 15 mutational density and summary features were downloaded for 1,188 tumours 32 . We used linear mixed-effect models to associate each feature with hypoxia score across cancers and compared each full model with a null model. Cancer type and sex were used as random effect variables. Tumours belonging to cancer types with fewer than 15 samples were excluded from the analysis. A Bonferroni p-value adjustment was applied to the p-values from linear mixed-effect modeling since fewer than 20 tests were conducted.
Driver Mutations Analysis
Data for driver mutations was first summarized at the gene level for 1,096 tumours with previously published driver mutation data 33 . For each of the 653 driver features, 
Mutational Signature Analysis
Previously published data for mutations attributed to various specific signatures was downloaded for 1,188 tumours 
Subclonality Analysis
Previously reported 37 subclonal reconstruction data was used to summarize the number of clonal and subclonal mutations in all 1,188 tumours. We used linear mixed-effect models to associate the number of these timed mutations with hypoxia score and compared each full model with a null model. Cancer type and sex were used as random effect variables. Tumours belonging to cancer types with fewer than 15 samples were excluded from the analysis. A Bonferroni adjustment was applied to the p-values from linear mixed-effect modeling since fewer than 20 tests were conducted.
The number of subclones was calculated for all 1,188 tumours based on the number of clusters of cells identified in each sample. A linear mixed-effects model were used to associate the number of subclones with hypoxia score and this model was compared to a null model. Cancer type was used as a random effect. Tumours belonging to cancer types with fewer than 15 samples were excluded from the analysis.
Patients with only one identified cluster of cells were defined as monoclonal and patients with more than one identified cluster of cells were defined as polyclonal 36 .
Hypoxia scores were median dichotomized to classify patients as hypoxic or shown along the left based on data from Bhandari et al. 16 . CNAs and SNVs in several genes were found to be associated with elevated hypoxia within tumour types.
Hypoxia was also associated with elevated PGA in 10 tumour types. The right side of the figure partially summarizes the analyses carried out in this work. Several of the previous intra-tumour type findings have been extended in this work as pan-cancer features of hypoxia and several novel features, particularly related to structural variants, have been assessed and found to be significantly associated with hypoxia.
This is in addition to the novel pan-caner work presented around single-base substitution signatures, indel signatures and tumour subclonality.
Supplementary Table Legends
Supplementary 
Supplementary Table 3 -Mutational density data by deciles
For each of the 15 mutational features analyzed, the value corresponding to each decile is provided.
Supplementary Table 4 -Hypoxia associated mutational density features
Results from linear mixed-effect models associating hypoxia with mutational density features while controlling for cancer type, age and sex.
Supplementary Table 5 -Hypoxia associated driver mutations
Results from linear mixed-effect models associating hypoxia with driver mutations while controlling for cancer type, age and sex.
Supplementary Table 6 -Hypoxia associated single base substitution signatures
Results from linear mixed-effect models associating hypoxia with the proportion of mutations attributed to single base substitution signatures while controlling for cancer type, age and sex.
Supplementary Table 7 -Hypoxia associated small insertion and deletion signatures
Results from linear mixed-effect models associating hypoxia with the proportion of mutations attributed to small insertion and deletion signatures while controlling for cancer type, age and sex.
